Science & Health · Health · 4 outlets (L 0 · C 1 · R 2 · 1 not rated)
FDA approves generic of twice-yearly HIV-prevention shot
The U.S. Food and Drug Administration has approved the first generic version of lenacapavir, the world's only twice-a-year shot to prevent HIV.[1, 2] IJR reported the generic will cost about $40 a year in 120 resource-limited countries, while the U.S. brand version lists at $28,218.[2] ABC News reported the approval raises hopes for access in low-income countries.[1]
Why it matters The approval makes the shot available at about $40 a year in 120 resource-limited countries, compared with the U.S. brand price of $28,218.[2]
Covered by ABC News, The Washington Times, Science and 1 more
Read first Approval of cheap version of HIV-prevention shot raises hopes in low-income countries
How balanced is this coverage?
Of the 3 rated outlets that covered it, 0 are left of center, 1 is center and 2 are right of center (2 of them in the Right group). 1 more is not rated.
Too few left- or right-leaning outlets to compare: 0 of 42 left-leaning, 1 of 33 center and 2 of 38 right-leaning outlets covered it.
- Left: none.
- Leans left: none.
- Center: ABC News (−0.19).
- Leans right: none.
- Right: The Washington Times (+1.27), IJR (+1.52).
Not rated Science. Not placed: they have no lean score.
Each dot is an outlet that covered it, placed by its audience-lean score (Eady et al. 2025), which measures who shares its links, not how accurate it is. The ticks under the line are all 113 rated outlets Tare reads.
Read across the spectrum
- Left-leaning No left-leaning outlet in Tare's list covered it.
- Center Approval of cheap version of HIV-prevention shot raises hopes in low-income countries
- Right-leaning FDA approves first generic twice-yearly HIV-prevention shot